Molina Healthcare, Inc. provides managed health care services to low-income families and individuals under the Medicaid and Medicare programs and through the state insurance marketplaces. It operates in four segments, Medicaid, Medicare, Marketplace, and Other. As of December 31, 2021, the company served the company served approximately 5.2 million members eligible for Medicaid, Medicare, and other government-sponsored healthcare programs in 18 states. The company was founded in 1980 and is headquartered in Long Beach, California.

Molina Healthcare, Inc.

The U.S. healthcare sector is navigating a turbulent landscape, shaped by rising medical costs, regulatory scrutiny and evolving patient behavior. Health insurers are under pressure as increasing utilization and reimbursement challenges test margins.

UnitedHealth vs. Molina: Who's Poised for the Healthiest Comeback?

After a period of underperformance, Centene's stock (NYSE:CNC) has recently seen a strong rebound, rising 6% on September 24 and nearly 20% over the last month. This follows a significant drop in July 2025 after the company withdrew its 2025 financial guidance.

CNC Stock or Molina Healthcare?

NEW YORK, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Molina Healthcare, Inc. (“Molina” or the “Company”) (NYSE: MOH).  Such investors are advised to contact Danielle Peyton at  newaction@pomlaw.com  or 646-581-9980, ext. 7980.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Molina Healthcare, Inc. - MOH

NEW YORK , Sept. 8, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Molina Healthcare, Inc. ("Molina" or the "Company") (NYSE: MOH).

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Molina Healthcare, Inc. - MOH

NEW YORK, Sept. 06, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Molina Healthcare, Inc. (“Molina” or the “Company”) (NYSE: MOH).

Barclays analyst Andrew Mok raised the firm's price target on UnitedHealth to $362 from $337 and keeps an Overweight rating on the shares. The firm adjusted estimates and targets in the managed care and healthcare facility group following a "volatile" Q2 earnings season. Group valuations have increased recently, which may be a sign that investor sentiment and estimates have bottomed out, the analyst tells investors in a research note. From here, Barclays sees a number of potential catalysts including September budget deals, final pricing for Medicare Advantage and Affordable Care Act plans and Medicare Advantage star ratings for the 2027 plans. Relative to estimates, the firm believes UnitedHealth (UNH) and CVS Health (CVS) offer the most near-term upside while Molina Healthcare (MOH) has the most downside risk.

UnitedHealth price target raised to $362 from $337 at Barclays

Barclays lowered the firm's price target on Molina Healthcare to $185 from $186 and keeps an Equal Weight rating on the shares. The firm adjusted estimates and targets in the managed care and healthcare facility group following a "volatile" Q2 earnings season. Group valuations have increased recently, which may be a sign that investor sentiment and estimates have bottomed out, the analyst tells investors in a research note. From here, Barclays sees a number of potential catalysts including September budget deals, final pricing for Medicare Advantage and Affordable Care Act plans and Medicare Advantage star ratings for the 2027 plans. Relative to estimates, the firm believes UnitedHealth (UNH) and CVS Health (CVS) offer the most near-term upside while Molina Healthcare (MOH) has the most downside risk. 23 Oct

Molina Healthcare price target lowered to $185 from $186 at Barclays

Barclays analyst Andrew Mok raised the firm's price target on Humana to $325 from $275 and keeps an Equal Weight rating on the shares. The firm adjusted estimates and targets in the managed care and healthcare facility group following a "volatile" Q2 earnings season. Group valuations have increased recently, which may be a sign that investor sentiment and estimates have bottomed out, the analyst tells investors in a research note. From here, Barclays sees a number of potential catalysts including September budget deals, final pricing for Medicare Advantage and Affordable Care Act plans and Medicare Advantage star ratings for the 2027 plans. Relative to estimates, the firm believes UnitedHealth (UNH) and CVS Health (CVS) offer the most near-term upside while Molina Healthcare (MOH) has the most downside risk.

Humana price target raised to $325 from $275 at Barclays

Barclays raised the firm's price target on Elevance Health to $373 from $327 and keeps an Overweight rating on the shares. The firm adjusted estimates and targets in the managed care and healthcare facility group following a "volatile" Q2 earnings season. Group valuations have increased recently, which may be a sign that investor sentiment and estimates have bottomed out, the analyst tells investors in a research note. From here, Barclays sees a number of potential catalysts including September budget deals, final pricing for Medicare Advantage and Affordable Care Act plans and Medicare Advantage star ratings for the 2027 plans. Relative to estimates, the firm believes UnitedHealth (UNH) and CVS Health (CVS) offer the most near-term upside while Molina Healthcare (MOH) has the most downside risk. 11 Sep

Elevance Health price target raised to $373 from $327 at Barclays

Barclays analyst Andrew Mok raised the firm's price target on CVS Health to $87 from $80 and keeps an Overweight rating on the shares. The firm adjusted estimates and targets in the managed care and healthcare facility group following a "volatile" Q2 earnings season. Group valuations have increased recently, which may be a sign that investor sentiment and estimates have bottomed out, the analyst tells investors in a research note. From here, Barclays sees a number of potential catalysts including September budget deals, final pricing for Medicare Advantage and Affordable Care Act plans and Medicare Advantage star ratings for the 2027 plans. Relative to estimates, the firm believes UnitedHealth (UNH) and CVS Health (CVS) offer the most near-term upside while Molina Healthcare (MOH) has the most downside risk.

CVS Health price target raised to $87 from $80 at Barclays

Barclays raised the firm's price target on Cigna to $383 from $354 and keeps an Overweight rating on the shares. The firm adjusted estimates and targets in the managed care and healthcare facility group following a "volatile" Q2 earnings season. Group valuations have increased recently, which may be a sign that investor sentiment and estimates have bottomed out, the analyst tells investors in a research note. From here, Barclays sees a number of potential catalysts including September budget deals, final pricing for Medicare Advantage and Affordable Care Act plans and Medicare Advantage star ratings for the 2027 plans. Relative to estimates, the firm believes UnitedHealth (UNH) and CVS Health (CVS) offer the most near-term upside while Molina Healthcare (MOH) has the most downside risk. 30 Oct

Cigna price target raised to $383 from $354 at Barclays

Barclays analyst Andrew Mok lowered the firm's price target on Centene to $33 from $45 and keeps an Equal Weight rating on the shares. The firm adjusted estimates and targets in the managed care and healthcare facility group following a "volatile" Q2 earnings season. Group valuations have increased recently, which may be a sign that investor sentiment and estimates have bottomed out, the analyst tells investors in a research note. From here, Barclays sees a number of potential catalysts including September budget deals, final pricing for Medicare Advantage and Affordable Care Act plans and Medicare Advantage star ratings for the 2027 plans. Relative to estimates, the firm believes UnitedHealth (UNH) and CVS Health (CVS) offer the most near-term upside while Molina Healthcare (MOH) has the most downside risk.

Centene price target lowered to $33 from $45 at Barclays

NEW YORK , Sept. 3, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Molina Healthcare, Inc. ("Molina" or the "Company") (NYSE: MOH).

NEW YORK, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Molina Healthcare, Inc. (“Molina” or the “Company”) (NYSE: MOH). Such investors are advised to contact Danielle Peyton at  newaction@pomlaw.com  or 646-581-9980, ext. 7980.

CHICAGO--(BUSINESS WIRE)--Prism and Molina Healthcare of Illinois partner to launch statewide “Ready by 10/15” back‑to‑school health records check hotline and mobile clinics.

Prism and Molina Healthcare of Illinois Partner to Launch Statewide “Ready by 10/15” Back‑to‑School Health Records Check Hotline and Mobile Clinics

NEW YORK, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Molina Healthcare, Inc. (“Molina” or the “Company”) (NYSE: MOH).  Such investors are advised to contact Danielle Peyton at  newaction@pomlaw.com  or 646-581-9980, ext. 7980.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Molina Healthcare, Inc. - MOH

Molina (MOH) reported earnings 30 days ago. What's next for the stock?

Why Is Molina (MOH) Up 9.2% Since Last Earnings Report?

Real-time stock quote and overview for MOH